As a follow up, the Commission intends to intensify its scrutiny of the pharmaceutical sector under EC antitrust law, including continued monitoring of settlements between originator and generic drug companies.
Uuringu tulemusel kavatseb komisjon süvendada farmaatsiasektori kontrollimist EÜ konkurentsiõiguse alusel ning jätkata originaalravimite ja geneeriliste ravimite tootjate vahel sõlmitavate patendikokkulepete jälgimist.